available upto August, 1985 and quick index for September, 1985, the rate of industrial growth during April—September, 1985 was 6.3 per cent over April—September, 1984. During January—June, 1985, the number of foreign collaboration approvals was 440 compared to 336 during the corresponding period of 1984, thus recording an increase of 31 per cent.

(d) The Government have been taking several measures to stimulate industrial production through appropriate changes in industrial licensing and import policies, as well as through monetary and fiscal measures and improvement in infrastruc ture.

Violation of condition of industrial licence by German Remedies

2863. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstam 1 Question 2218 given in the Rajya Sabha on the 19th August, 1985 and state:

(a) whether violation of condition of Industrial Licence by German Remedies has been established;

(b) if so, what action has been laken against the company;

(c) whether it is a fact that Merck Sharp & Dhome are still marketing the formula tions based on Cyproheptadine Hcl;

d) if so, what is the source of availability of the bulk drug to this company,

(e) whether Merck Sharp is allowed to import Cyproheptadine according to the condition of Industrial Licence granted to them;

(f) what are the main conditions of Industrial Licence and what is the capacity allowed for Cyproheptadine and its formulations; and

(g) what are the details of action taken against Glaxo for the contravention of Licence condition in regard to import of Triene?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRi R. K. JAICHANDRA SINGH): (a) Yes, Sir.

(b) Action against M|s, German Remedies for import of Oxyfedrine in violation of the conditions of the Industrial Licence is on.

(c) and (d) The information is being collected and will be laid on the Table of the House.

(e) and (f) The following are the conditions laid down in the Industrial Licence issued in December, 1962:—

1. that no additional plant and machinery will be required tor this activity;

2. that no royalty or any fee or any other similar payment will be permissible;

3. that the product will be marketed with the trade mark already in use;

4. that no foreign personnel will be required;

5. that no special concession in regard to the import of basic raw materials and ingredients will be sought in relaxation of the general policy i^ force from time to time.

6. that no additional foreign exchange will be made available for this activity.

(g) Action is being taken by the Ministry of Agriculfure for contravention of the Licensing condition by Glaxo in regard to the import of Triene.

Consumption of energy

2864. SHRI LAL K. ADVANI: Will the Minister of ENERGY be pleased to refer to the answer to Unstarred Question 2156 given in the Rajya Sabha on the 9th December, 1985 and state whether it is a fact that recent studies have shown that India consumes double the energy for producing materials of the same value internationally, resulting not only in high costs but also in enormous wastage of energy and if so, what are the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF POWER (SHRI ARIF MOHD, KHAN); According to broad assessments available, it can be said that some industries in India, e.g. Steel Plant, consume considerably more energy for producing material of the same value as compared to some of the advanced countries

of the world. The Inter-Ministerial Working Group on Utilisation and Conservation of Energy has assessed a potential for 25 per cent saving of energy in the industrial sector by introducing energy conservation measures.

Unintended benefit on Doxyedline and Gentamycin

2865. DR. JOSEPH LEON D'SOUZA: Will the Minister of INDUSTRY be pleased to refer to the answer *to* Unstarred Question 2314 given in the Rajya Sabha on the 19th August, 1985 and state:

(a) what is the name of each formulator in whose favour amount has been worked out as unintended benefit made on Doxy-cycline and Gentamycin alongwith the details of quantity of each and price difference per kg, as well as the total amount against each formulator;

(b) when was the amount communicated to each formulator and whether any recovery has been made;

(c) if so, the name of each company item involved and amount recovered from each;

(d) whether it is a fact that Gentamycin and Doxycycline are available at much cheaper prices than the notified prices and the formulators are continuing making un-intended benefits;

(e) if so, what is the present market price of each formulation; and

(f) what are the details of steps taken by Government to see that the benefit of price control reaches the consumer rather than allowing the drug formulators to make unintended benefits?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R- K. JAI-CHANDRA SINGH): (a) to (c) Names of the companies who have been given notices for recovery of the difference between price allowed in the formulations and actual import | procurement price of Gentamycin and Doxycycline have already been furnished in reply *to* Rajya Sabha Unstarred Question No. 2314 answered on 19th August, 1985. The elaborate process of scrutinising the invoices so as to work out the amount due from each company is on.

An amount of 194.62 lakhs as due into the Drug Prices Equalisation Account was communicated to M|s. Fulford India Ltd. in regard to Gentamycin. This company filed a writ petition in the Delhi High Court and obtained stay to the recovery.

No amount has so far been recovered from any formulator in respect of Gentamycin and Doxycycline.

(d) and (e) The price notified by the Government is the maximum sale price and the manufacturers are free to sell bulk drugs and formulations at prices not exceeding the prices fixed by the Government. A Statement showing the leader prices °f Doxycycline and Gentamycin formulations as currently in vogue is attached.

(f) Price Control on drugs under the Drugs (Prices Control) Order has helped to moderate the prices and the benefit has flowed to the consumer.

Statement

	Name of the formulation and strength	Pack Size	Leader price excluding Excise Duty as fixed by the Government
1	2	3	4
1	Doxycycline Capsules 100mg./Capsule . .	2 Caps	4·51
		3 Caps	6·27
		4 Caps	6·87
		6 Caps.	7 54
		10's Strip	17·18